CAPS:OTCQB-Capstone Therapeutics Crp

COMMON STOCK | Biotechnology | OTCQB - U.S. Registered

Last Closing

USD 14.1

Change

0.00 (0.00)%

Market Cap

USD 3.19M

Volume

N/A

Analyst Target

USD 0.00
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Capstone Therapeutics Corp is a biotechnology company engaged in developing a pipeline of novel peptides and other molecules aimed at helping patients with under-served medical conditions.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-10-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NONOF Novo Nordisk A/S

+0.06 (+0.05%)

USD 564.56B
CSLLY CSL Ltd

-2.01 (-2.20%)

USD 91.31B
CMXHF CSL Limited

N/A

USD 89.03B
ARGNF argenx SE

N/A

USD 23.23B
UCBJF UCB SA

+3.05 (+2.48%)

USD 23.19B
UCBJY UCB SA ADR

-0.87 (-1.37%)

USD 22.77B
GNMSF Genmab A/S

-9.12 (-3.13%)

USD 19.46B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 7.83B
WXIBF WuXi Biologics

-0.11 (-5.97%)

USD 7.52B
WXXWY WuXi Biologics (Cayman) Inc

-0.09 (-2.61%)

USD 7.10B

ETFs Containing CAPS

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (OTCQB - U.S. Registered)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 78,233.33% 100% F 100% F
Dividend Return N/A N/A N/A N/A F
Total Return 78,233.33% 100% F 100% F
Trailing 12 Months  
Capital Gain 27,015.38% 99% N/A 100% F
Dividend Return N/A N/A N/A N/A F
Total Return 27,015.38% 99% N/A 99% N/A
Trailing 5 Years  
Capital Gain 6,003.90% 97% N/A 98% N/A
Dividend Return N/A N/A N/A N/A F
Total Return 6,003.90% 97% N/A 98% N/A
Average Annual (5 Year Horizon)  
Capital Gain 498.74% 92% A 94% A
Dividend Return 498.74% 92% A 94% A
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 3,612.89% 6% D- 4% F
Risk Adjusted Return 13.80% 55% F 48% F
Market Capitalization 3.19M 27% F 32% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Negative Book Value

The company has negative book value.